MDA Cells in Hormone Receptor Modulation Studies

As pioneers in cell line development and distribution, Cytion's MDA cell lines have become indispensable tools in hormone receptor research. Our MDA-MB-231 and MDA-MB-468 cell lines provide researchers with robust models for investigating hormone receptor pathways, particularly in breast cancer research. This article explores how these versatile cell models contribute to advancing our understanding of hormone modulation mechanisms.

MDA-MB-231: The Gold Standard for Triple-Negative Breast Cancer Research

The MDA-MB-231 cell line has established itself as the cornerstone of triple-negative breast cancer (TNBC) research at Cytion. Derived from a pleural effusion of a 51-year-old Caucasian female with metastatic adenocarcinoma, these cells are characterized by their triple-negative receptor status (ER-/PR-/HER2-), making them invaluable for studying hormone-independent cancer mechanisms. Their aggressive phenotype, high proliferation rate, and remarkable metastatic potential in vivo have positioned MDA-MB-231 as the preferred model for investigating cancer invasion pathways and testing novel therapeutic approaches for hormone-resistant tumors. Researchers utilizing our MDA-MB-231 cells consistently report robust experimental reproducibility and physiological relevance, particularly in studies exploring the interplay between inflammatory signaling and metastatic progression.

MDA-MB-468: Unraveling EGFR-Driven Pathways in Hormone-Independent Cancers

Our MDA-MB-468 cell line represents another critical model in Cytion's portfolio for hormone receptor modulation research. These cells exhibit the defining triple-negative phenotype while uniquely overexpressing epidermal growth factor receptor (EGFR), making them exceptionally valuable for investigating EGFR-dependent signaling mechanisms in the absence of classical hormone receptors. Derived from a pleural effusion of a 51-year-old Black female with metastatic adenocarcinoma, MDA-MB-468 cells display distinctive morphological characteristics and growth patterns compared to other TNBC models. The cell line's documented resistance to multiple targeted therapies creates an ideal experimental system for studying resistance mechanisms and developing circumvention strategies. Recent collaborative projects using our MDA-MB-468 cells have identified novel cross-talk between EGFR and non-canonical hormone signaling pathways, potentially opening new therapeutic avenues for previously treatment-resistant cancers.

MDA-MB-453: Exploring HER2 Amplification and Androgen Receptor Dynamics

The MDA-MB-453 cell line stands out in Cytion's collection due to its distinct receptor profile: negative for estrogen and progesterone receptors (ER-/PR-) but positive for HER2 amplification. This unique profile makes it an exceptional model for investigating HER2-driven oncogenic signaling pathways independent of classical hormone receptors. What further distinguishes MDA-MB-453 cells is their significant androgen receptor (AR) expression, creating an invaluable research tool for exploring the emerging role of androgen signaling in breast cancer progression. Studies with our MDA-MB-453 line have revealed sophisticated crosstalk between HER2 and AR pathways, challenging traditional views of receptor-driven cancer biology. The cell line exhibits distinctive responses to HER2-targeted therapies such as trastuzumab and lapatinib, enabling researchers to investigate resistance mechanisms and develop combination therapy approaches targeting both HER2 and AR signaling. This dual-receptor characteristic has positioned MDA-MB-453 at the forefront of precision medicine research for molecular subtype-specific treatment strategies.

MDA-MB-436: Illuminating BRCA1 Mutation Effects on DNA Repair Pathways

Cytion's MDA-MB-436 cell line serves as a critical model for investigating the intricate relationship between hormone receptor status and genomic integrity maintenance. Derived from the pleural effusion of a 43-year-old female with metastatic adenocarcinoma, these cells harbor a naturally occurring BRCA1 mutation (5396+1G>A in intron 20) alongside their triple-negative receptor profile. This combination makes MDA-MB-436 an exceptional platform for studying how BRCA1 deficiency influences DNA repair mechanisms in the absence of hormone receptor signaling. Our clients have successfully employed this cell line to evaluate PARP inhibitor sensitivity, homologous recombination deficiency, and synthetic lethal therapeutic approaches. The MDA-MB-436 line exhibits characteristic genomic instability patterns and heightened sensitivity to DNA-damaging agents, creating an authentic model that closely mimics clinical BRCA1-mutated triple-negative breast cancers. Researchers utilizing these cells have uncovered novel connections between hormone-independent growth pathways and compromised DNA repair mechanisms, expanding our understanding of how these cellular processes interact in aggressive cancer phenotypes.